Compare BCBP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | GANX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 117.7M |
| IPO Year | N/A | 2021 |
| Metric | BCBP | GANX |
|---|---|---|
| Price | $8.17 | $3.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $9.25 | $8.00 |
| AVG Volume (30 Days) | 79.7K | ★ 1.3M |
| Earning Date | 10-27-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $64,592,000.00 | N/A |
| Revenue This Year | $23.06 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $164.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.41 | $1.41 |
| 52 Week High | $13.37 | $3.65 |
| Indicator | BCBP | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 68.58 |
| Support Level | $7.85 | $2.92 |
| Resistance Level | $8.12 | $3.65 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 85.71 | 90.45 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.